Hale Therapeutics
Proprietary medical vaporizer and mobile application to help smokers quit nicotine more easily
Overview
Raised: $26,500
Total Commitments ($USD)
SeedInvest
02/28/2022
07/13/2022
$1,000
Convertible Note
Seed
RegCF
/ RegD 506(c)
$15,000,000
20%
2018
Healthcare & Pharmaceuticals
Biotech
B2C
Medium
Low
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-641,293 |
$-430,338 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$757,219 |
$721,754 |
|
Accounts Receivable |
$49,551 |
$68,982 |
|
Total Assets |
$852,260 |
$796,426 |
|
Short-Term Debt |
$1,962,128 |
$1,265,078 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$1,962,128 |
$1,265,078 |
Raise History
| Offering Name | Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Hale Therapeutics | 07/13/2022 | SeedInvest | $15,000,000 | $26,500 | Convertible Note | Not Funded | RegCF / RegD 506(c) |
No prior online funding rounds.
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Founder Profile
Hale Therapeutics Founder Josh Israel Is Determined to Help Smokers Quit
Once upon a time, cigarette companies marketed their products with the promises of healing properties and the trustworthy faces of dentists, babies, and Santa Claus. Today the health consequences of smoking tobacco are well known, and most smokers want to quit. But despite modern advancements in medicine and technology, quitting success rates remain dismally low.Hale Therapeutics is on a mission to help smokers quit with a new method: smoking. The company has created a patented dual-capsule vaporizer that will gradually ease smokers off of nicotine with steps that may be familiar to them. We reached out to co-founder and CEO Josh Israel to learn about the origin of Hale Therapeutics and where the company might go from here.
Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.